Rebecca Sarac
Dermatology · Stamford, CTNPI 1124588918
Payments from drug & device makers
Across 300 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$743
- Sanofi$733
- Incyte Corporation$570
- UCB, Inc.$358
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,66297%
- Education$1953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 52 | $1,331 |
| AbbVie | 52 | $1,016 |
| Regeneron Healthcare Solutions, Inc. | 37 | $743 |
| Sanofi | 25 | $733 |
| Incyte Corporation | 29 | $570 |
| UCB, Inc. | 11 | $358 |
| LEO Pharma Inc. | 17 | $303 |
| Sun Pharmaceutical Industries Inc. | 15 | $266 |
| Lilly USA, LLC | 8 | $201 |
| Amgen | 8 | $182 |
| Arcutis Biotherapeutics, Inc. | 8 | $177 |
| Boehringer Ingelheim | 5 | $118 |
| Pfizer | 5 | $112 |
| E.r. Squibb & Sons, L.L.C. | 4 | $108 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Dermavant Sciences, Inc. | 4 | $91 |
| Novartis | 3 | $80 |
| Botanix SB Inc | 3 | $74 |
| Organon | 4 | $72 |
| Biofrontera Inc. | 1 | $69 |
| Galderma Laboratories, L.p. | 2 | $44 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $36 |
| Genentech USA, Inc. | 2 | $34 |
| Blueprint Medicines Corporation | 1 | $30 |
| Strata Skin Sciences, Inc. | 1 | $14 |
How this compares
$6,857 in reported general payments places this provider in the 65th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 153 | $2,453 |
| Clobetasol Propionate | 42 | $1,861 |
| Fluorouracil | 14 | $1,049 |
| Fluocinonide | 25 | $879 |
| Metronidazole | 20 | $862 |
| Clindamycin Phosphate | 16 | $793 |
| Triamcinolone Acetonide | 81 | $614 |
| Doxycycline Hyclate | 25 | $418 |
| Hydrocortisone | 27 | $180 |
| Mupirocin | 20 | $145 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Stamford
- Brett KingFairfield$6.1M
- Michael PayetteCromwell$3.4M
- Bruce StroberCromwell$3.3M
- Lisa DonofrioNew Haven$2.3M
- Mona ShahriariCromwell$2.3M
- Jeremy MossMadison$2.2M
- Brittany CraiglowFairfield$1.9M
- Meagen McCuskerEnfield$1.8M
- Christopher BunickNew Haven$1.7M
- Jun LuFarmington$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.